文献速递心律失常

ENGAGE AF-TIMI 48 试验:房颤患者体重指数与结局的关系

Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.
PubMed 文献 · Eur Heart J · 2019-01-01

在 ENGAGE AF-TIMI 48 试验的 21 028 例房颤患者中,按 BMI 分层分析显示,BMI 每增加 5 kg/m2 与卒中/体循环栓塞风险降低(HR 0.88)和死亡风险降低(HR 0.91)独立相关,但与大出血风险增加(HR 1.06)相关。艾多沙班与华法林在各 BMI 组中的疗效和安全性相似。

要点

  • BMI 升高与房颤患者卒中/体循环栓塞及死亡风险降低独立相关。
  • BMI 升高同时与大出血及临床相关非大出血风险增加相关。
  • 艾多沙班与华法林在不同 BMI 组间的疗效和安全性相似。

核心结论

  • BMI 升高独立关联卒中/体循环栓塞风险降低和生存改善,但出血风险增加。
  • 艾多沙班在各 BMI 组(18.5 至 >40 kg/m2)的疗效与安全性特征相似。

研究设计与样本

  • ENGAGE AF-TIMI 48 试验的队列分析,共纳入 21 028 例房颤患者。
  • 患者随机接受华法林(INR 2.0-3.0)或艾多沙班治疗,按 BMI 分类:低体重(<18.5)0.8%、正常(18.5 至 <25)21.4%、超重(25 至 <30)37.6%、中度肥胖(30 至 <35)24.8%、重度肥胖(35 至 <40)10.0%、极重度肥胖(≥40)5.5%。

主要发现

  • BMI 每增加 5 kg/m2,卒中/体循环栓塞风险 HR 0.88(P = 0.0001),缺血性卒中/体循环栓塞 HR 0.87(P < 0.0001),死亡 HR 0.91(P < 0.0001)。
  • BMI 每增加 5 kg/m2,大出血风险 HR 1.06(P = 0.025),大出血或临床相关非大出血 HR 1.05(P = 0.0007)。
  • 性别与 BMI 分类存在显著交互作用,男性缺血性卒中/体循环栓塞风险降低,女性出血风险增加。
  • BMI >18.5 kg/m2 各组间艾多沙班谷浓度和抗 Xa 活性相似,华法林治疗窗内时间随 BMI 增加显著改善(P < 0.0001)。

临床怎么用

  • 房颤患者评估卒中和出血风险时应考虑 BMI,高 BMI 患者可能卒中风险较低但出血风险较高。
  • 艾多沙班在不同 BMI 组间的疗效和安全性相似,支持其在此类人群中的使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To investigate the relationship between body mass index (BMI) and outcomes in patients with atrial fibrillation (AF). METHODS AND RESULTS: In the ENGAGE AF-TIMI 48 trial, patients with AF were randomized to warfarin (international normalized ratio 2.0-3.0) or edoxaban. The cohort (N = 21 028) included patients across BMI categories (kg/m2): underweight (<18.5) in 0.8%, normal (18.5 to <25) in 21.4%, overweight (25 to <30) in 37.6%, moderately obese (30 to <35) in 24.8%, severely obese (35 to <40) in 10.0%, and very severely obese (≥40) in 5.5%. In an adjusted analysis, higher BMI (continuous, per 5 kg/m2 increase) was significantly and independently associated with lower risks of stroke/systemic embolic event (SEE) [hazard ratio (HR) 0.88, P = 0.0001], ischaemic stroke/SEE (HR 0.87, P < 0.0001), and death (HR 0.91, P < 0.0001), but with increased risks of major (HR 1.06, P = 0.025) and major or clinically relevant non-major bleeding (HR 1.05, P = 0.0007). There was a significant interaction between sex and increasing BMI category, with lower risk of ischaemic stroke/SEE in males and increased risk of bleeding in women. Trough edoxaban concentration and anti-Factor Xa activity were similar across BMI groups >18.5 kg/m2, while time in therapeutic range for warfarin improved significantly as BMI increased (P < 0.0001). The effects of edoxaban vs. warfarin on stroke/SEE, major bleeding, and net clinical outcome were similar across BMI groups. CONCLUSION: An increased BMI was independently associated with a lower risk of stroke/SEE, better survival, but increased risk of bleeding. The efficacy and safety profiles of edoxaban were similar across BMI categories ranging from 18.5 to >40.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Boriani G, Ruff CT, Kuder JF, et al. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2019. PMID: 30624719. doi:10.1093/eurheartj/ehy861

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。